Shionogi Antimicrobial stewardship program
Active Since: 2010
Contributing to SDGs…
SHIONOGI has been working to improve access to our innovative medicines through alliances and licensing partnerships with other global companies. Contributing to our core business model through alliances and licensing, we recognise the importance of considering access provisions in possible future partnership agreements related to AMR.
Shionogi & Co., Ltd.Company Profile
The program aims to implement the following initiatives to ensure all antimicrobials, not just those made by Shionogi, are used appropriately.
What are the health needs and challenges?
At Shionogi, antimicrobial stewardship means selecting the best medicine and administration method and ensuring treatment starts and ends at the optimal time, in order to make treatment safe and reliable, prevent the spread of drug-resistant bacteria and viruses, and support the effective use of healthcare resources.
Description of partnership activities and how they address needs and challenges
In July 2010, Shionogi established a special unit promoting appropriate use of anti-infective drugs.
The mission of this unit is:
Adhere to the highest ethical standard in promotion of antibiotics.
Support continuing medical education from anti-infective Key Opinion Leaders to Health Care Professionals (HCP) regarding appropriate use of antibiotics (Lecture, Web conference, Radio broadcasting, Support tools of countermeasures against nosocomial infection etc.)
Share relevant information on appropriate use to HCPs (Symposium, Lecture at medical office etc.)
Engage in research and development of anti-infective innovative medicine and diagnostics.
Conduct surveillance for susceptibility of antibiotics, at approximately 20 medical institutes in Japan.
Corresponding principle in the declaration
“We are committed to antibiotics only being used in patients who need them, we support continued education for clinical professionals on appropriate use, and we welcome the WHO Global Action Plan’s focus on improved stewardship”.
Read full Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.3: Communicable Diseases & NTDs
SDG 9: Industry Innovation and Infrastructure
SDG 17: Partnerships for the Goals
- Taiwan, Province of China
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)